See the latest news and media coverage for Simsen Diagnostics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Ultra-sensitive ctDNA analysis provider
simsendiagnostics.comLast updated
In short: Simsen Diagnostics expanded its European reach through new clinical collaborations and the launch of its ctDNA monitoring solutions.
Studies using SiMSen-Seq detected ctDNA rises months before scans in rhabdomyosarcoma and neuroblastoma patients. They offer full-service monitoring and Personal LabSuite, seeking European partners.
Simsen deploys Simsen® Personal to monitor ctDNA in the Phase 1/2 trial evaluating TH9619 for solid cancers. The collaboration aims to detect minimal residual disease and guide dosing.
Partners with Swedish hospital for tumour-informed ctDNA analysis. Provides panels, reagents, and support for seamless integration, efficiency, and precision oncology.
Simsen partners for ultrasensitive ctDNA analysis in Buzzard's Phase IIa colorectal cancer trial using SiMSen-Seq platform. CEOs express enthusiasm.
Track Simsen Diagnostics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Simsen Diagnostics and other trending companies.